Hyperhomocysteinemia enhances vascular inflammation and accelerates atherosclerosis in a murine model.

Although hyperhomocysteinemia (HHcy) is a well-known risk factor for the development of cardiovascular disease, the underlying molecular mechanisms are not fully elucidated. Here we show that induction of HHcy in apoE-null mice by a diet enriched in methionine but depleted in folate and vitamins B6 and B12 increased atherosclerotic lesion area and complexity, and enhanced expression of receptor for advanced glycation end products (RAGE), VCAM-1, tissue factor, and MMP-9 in the vasculature. These homocysteine-mediated (HC-mediated) effects were significantly suppressed, in parallel with decreased levels of plasma HC, upon dietary supplementation with folate and vitamins B6/B12. These findings implicate HHcy in atherosclerotic plaque progression and stability, and they suggest that dietary enrichment in vitamins essential for the metabolism of HC may impart protective effects in the vasculature.

[1]  J. Kooner,et al.  Improved Vascular Endothelial Function After Oral B Vitamins: An Effect Mediated Through Reduced Concentrations of Free Plasma Homocysteine , 2000, Circulation.

[2]  J. Loscalzo,et al.  Endothelial dysfunction in a murine model of mild hyperhomocyst(e)inemia. , 2000, The Journal of clinical investigation.

[3]  J. Twisk,et al.  Effect of homocysteine-lowering treatment with folic acid plus vitamin B6 on progression of subclinical atherosclerosis: a randomised, placebo-controlled trial , 2000, The Lancet.

[4]  N. Dudman.  An alternative view of homocysteine , 1999, The Lancet.

[5]  A. Blann,et al.  Three months supplementation of hyperhomocysteinaemic patients with folic acid and vitamin B6 improves biological markers of endothelial dysfunction , 1999, British journal of haematology.

[6]  A. Szczeklik,et al.  Treatment of hyperhomocysteinemia with folic acid and vitamins B12 and B6 attenuates thrombin generation. , 1999, Thrombosis research.

[7]  H. Knapp,et al.  Role of oxidant stress in endothelial dysfunction produced by experimental hyperhomocyst(e)inemia in humans. , 1999, Circulation.

[8]  S. Yusuf,et al.  Homocyst(e)ine and Cardiovascular Disease: A Critical Review of the Epidemiologic Evidence , 1999, Annals of Internal Medicine.

[9]  R. D'Agostino,et al.  Nonfasting Plasma Total Homocysteine Levels and Stroke Incidence in Elderly Persons: The Framingham Study , 1999, Annals of Internal Medicine.

[10]  T. Podor,et al.  Homocysteine-induced endoplasmic reticulum stress and growth arrest leads to specific changes in gene expression in human vascular endothelial cells. , 1999, Blood.

[11]  G. Habib,et al.  Effects of folate supplementation in hyperhomocysteinemic pigs. , 1999, Journal of the American College of Cardiology.

[12]  M. Neurath,et al.  RAGE Mediates a Novel Proinflammatory Axis A Central Cell Surface Receptor for S100/Calgranulin Polypeptides , 1999, Cell.

[13]  E. Tremoli,et al.  Tissue factor in atherosclerosis. , 1999, Atherosclerosis.

[14]  M. Jeune,et al.  Effect of Matrix Metalloproteinase Inhibition on Progression of Atherosclerosis and Aneurysm in LDL Receptor‐Deficient Mice Overexpressing MMP‐3, MMP‐12, and MMP‐13 and on Restenosis in Rats after Balloon Injury , 1999, Annals of the New York Academy of Sciences.

[15]  V. Babaev,et al.  Atherosclerotic lesions of apolipoprotein E deficient mice contain cells expressing S100 protein. , 1999, Atherosclerosis.

[16]  A. Schmidt,et al.  Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. , 1999, Circulation research.

[17]  C. Luley,et al.  Response of hyperhomocysteinemia to folic acid supplementation in patients with end-stage renal disease. , 1999, Clinical nephrology.

[18]  S. Eichinger,et al.  Hyperhomocysteinemia Is a Risk Factor of Recurrent Venous Thromboembolism , 1998, Thrombosis and Haemostasis.

[19]  K. Hajjar,et al.  Modulation of annexin II by homocysteine: implications for atherothrombosis. , 1998, Journal of investigative medicine : the official publication of the American Federation for Clinical Research.

[20]  A. Schmidt,et al.  Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts , 1998, Nature Medicine.

[21]  K. Hajjar,et al.  Induction of Acute Translational Response Genes by Homocysteine , 1998, The Journal of Biological Chemistry.

[22]  P. Libby,et al.  Lipid lowering by diet reduces matrix metalloproteinase activity and increases collagen content of rabbit atheroma: a potential mechanism of lesion stabilization. , 1998, Circulation.

[23]  B. Chait,et al.  Tissue Plasminogen Activator Binding to the Annexin II Tail Domain , 1998, The Journal of Biological Chemistry.

[24]  P. Carmeliet,et al.  Urokinase-generated plasmin activates matrix metalloproteinases during aneurysm formation , 1997, Nature Genetics.

[25]  P. Durand,et al.  Acute methionine load‐induced hyperhomocysteinemia enhances platelet aggregation, thromboxane biosynthesis, and macrophage‐derived tissue factor activity in rats , 1997, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[26]  P. Libby,et al.  Activation of monocyte/macrophage functions related to acute atheroma complication by ligation of CD40: induction of collagenase, stromelysin, and tissue factor. , 1997, Circulation.

[27]  J. Fallon,et al.  Tissue Factor in the Pathogenesis of Atherosclerosis , 1997, Thrombosis and Haemostasis.

[28]  A. Schmidt,et al.  Characterization and Functional Analysis of the Promoter of RAGE, the Receptor for Advanced Glycation End Products* , 1997, The Journal of Biological Chemistry.

[29]  T. Miyata,et al.  Homocysteine-respondent Genes in Vascular Endothelial Cells Identified by Differential Display Analysis , 1996, The Journal of Biological Chemistry.

[30]  H. Hoeger,et al.  Homocysteine increases cyclin-dependent kinase in aortic rat tissue. , 1996, Circulation.

[31]  J. Loscalzo.  The oxidant stress of hyperhomocyst(e)inemia. , 1996, The Journal of clinical investigation.

[32]  M. Mirault,et al.  Inhibition of I kappa B-alpha phosphorylation and degradation and subsequent NF-kappa B activation by glutathione peroxidase overexpression , 1996, The Journal of cell biology.

[33]  W C Willett,et al.  Homocysteine metabolism and risk of myocardial infarction: relation with vitamins B6, B12, and folate. , 1996, American journal of epidemiology.

[34]  C. Heizmann,et al.  The S100 family of EF-hand calcium-binding proteins: functions and pathology. , 1996, Trends in biochemical sciences.

[35]  D. Zimmer,et al.  The S100 protein family: History, function, and expression , 1995, Brain Research Bulletin.

[36]  G. Omenn,et al.  A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. , 1995, JAMA.

[37]  N. Maeda,et al.  Mice deficient in cystathionine beta-synthase: animal models for mild and severe homocyst(e)inemia. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[38]  H. Tamai,et al.  Homocysteine induces iron-catalyzed lipid peroxidation of low-density lipoprotein that is prevented by alpha-tocopherol. , 1994, Free radical research.

[39]  R. Alexander,et al.  Vascular cell adhesion molecule-1 (VCAM-1) gene transcription and expression are regulated through an antioxidant-sensitive mechanism in human vascular endothelial cells. , 1993, The Journal of clinical investigation.

[40]  T. Collins.  Endothelial nuclear factor-kappa B and the initiation of the atherosclerotic lesion. , 1993, Laboratory investigation; a journal of technical methods and pathology.

[41]  Amyj . Williams,et al.  Functional analysis of the human vascular cell adhesion molecule 1 promoter , 1992, The Journal of experimental medicine.

[42]  B. Fleckenstein,et al.  Antioxidants selectively suppress activation of NF-kappa B by human T-cell leukemia virus type I Tax protein , 1992, Journal of virology.

[43]  N. Maeda,et al.  Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. , 1992, Science.

[44]  E. Rubin,et al.  Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells , 1992, Cell.

[45]  J. Sadler,et al.  Inhibition of thrombomodulin surface expression and protein C activation by the thrombogenic agent homocysteine. , 1991, The Journal of clinical investigation.

[46]  G. Rodgers,et al.  Homocysteine, an atherogenic stimulus, reduces protein C activation by arterial and venous endothelial cells. , 1990, Blood.

[47]  G. Rodgers,et al.  Activation of endogenous factor V by a homocysteine-induced vascular endothelial cell activator. , 1986, The Journal of clinical investigation.

[48]  R. Ross,et al.  Homocystinemia. Vascular injury and arterial thrombosis. , 1974, The New England journal of medicine.

[49]  J. Loscalzo,et al.  Homocysteine-induced nitric oxide production in vascular smooth-muscle cells by NF-kappa B-dependent transcriptional activation of Nos2. , 1998, Proceedings of the Association of American Physicians.

[50]  P. Guillausseau,et al.  Rapid Publication , 1971, Nature.

[51]  J. Stamler,et al.  Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen. , 1993, The Journal of clinical investigation.

[52]  K. Albermann,et al.  Nuclear Factor Kb: An Oxidative Stress-Responsive Transcription Factor of Eukaryotic Cells (A Review) , 1992 .

[53]  B. Vester,et al.  High Performance Liquid Chromatography Method for Rapid and Accurate Determination of Homocysteine in Plasma and Serum , 1991, European journal of clinical chemistry and clinical biochemistry : journal of the Forum of European Clinical Chemistry Societies.